Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Relapsed or Refractory Acute Leukemia
NCT01251965Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2010
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2010; status: terminated.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01251965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251965.